Altamira Therapeutics reported highlights from a peer reviewed article showing efficacy of oral betahistine in the treatment of posterior canal benign paroxysmal positional vertigo (BPPV) when administered along with a canal repositioning procedure, the Epley maneuver
Otonomy, Inc. a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear,...
Otonomy, Inc. announced results for its AVERTS-1 Phase III clinical trial of Otividex (dexamethasone sustained release) in patients with Ménière's...
Betahistine is indicated for treatment of Ménière's syndrome, symptoms of which may include vertigo, tinnitus, hearing loss and nausea
Betahistine is indicated for the treatment of vertigo, tinnitus and hearing loss associated with Meniere's syndrome.
Vertigo, tinnitus and hearing loss associated with Ménière's syndrome.
Otonomy, Inc., has announced that the Phase III clinical trial of Otividex (OTO 104) in patients with Ménière’s disease did not achieve the primary endpoint, which was the count of definitive vertigo days (DVD) in Month 3 for Otividex vs. placebo for the intent-to-treat (ITT) population (n = 148; p value = 0.312) using the Negative Binomial Model.